nodes	percent_of_prediction	percent_of_DWPC	metapath
Rufinamide—CYP2E1—Dacarbazine—muscle cancer	0.237	0.452	CbGbCtD
Rufinamide—CYP2E1—Etoposide—muscle cancer	0.116	0.221	CbGbCtD
Rufinamide—ALB—Methotrexate—muscle cancer	0.0742	0.141	CbGbCtD
Rufinamide—CYP3A4—Vincristine—muscle cancer	0.0384	0.0731	CbGbCtD
Rufinamide—CYP3A4—Etoposide—muscle cancer	0.0352	0.067	CbGbCtD
Rufinamide—CES1—larynx—muscle cancer	0.0303	0.179	CbGeAlD
Rufinamide—CYP3A4—Doxorubicin—muscle cancer	0.024	0.0457	CbGbCtD
Rufinamide—GRM5—head—muscle cancer	0.0086	0.0509	CbGeAlD
Rufinamide—GRM5—testis—muscle cancer	0.00831	0.0492	CbGeAlD
Rufinamide—SCN7A—cardiac atrium—muscle cancer	0.00727	0.043	CbGeAlD
Rufinamide—SCN11A—head—muscle cancer	0.00638	0.0378	CbGeAlD
Rufinamide—SCN4A—renal system—muscle cancer	0.00567	0.0336	CbGeAlD
Rufinamide—CES1—E2F transcription factor network—TFE3—muscle cancer	0.00545	0.0598	CbGpPWpGaD
Rufinamide—SCN7A—head—muscle cancer	0.00543	0.0322	CbGeAlD
Rufinamide—SCN7A—testis—muscle cancer	0.00524	0.0311	CbGeAlD
Rufinamide—Nystagmus—Vincristine—muscle cancer	0.00523	0.0244	CcSEcCtD
Rufinamide—SCN9A—tendon—muscle cancer	0.00496	0.0294	CbGeAlD
Rufinamide—SCN8A—head—muscle cancer	0.00484	0.0287	CbGeAlD
Rufinamide—SCN8A—testis—muscle cancer	0.00467	0.0277	CbGeAlD
Rufinamide—SCN4A—tendon—muscle cancer	0.00443	0.0262	CbGeAlD
Rufinamide—SCN3A—renal system—muscle cancer	0.00441	0.0261	CbGeAlD
Rufinamide—SCN9A—testis—muscle cancer	0.00411	0.0243	CbGeAlD
Rufinamide—SCN5A—cardiac atrium—muscle cancer	0.00394	0.0233	CbGeAlD
Rufinamide—Gait disturbance—Vincristine—muscle cancer	0.00383	0.0178	CcSEcCtD
Rufinamide—SCN4A—head—muscle cancer	0.00379	0.0225	CbGeAlD
Rufinamide—CES1—E2F transcription factor network—TP73—muscle cancer	0.00368	0.0404	CbGpPWpGaD
Rufinamide—SCN4A—testis—muscle cancer	0.00366	0.0217	CbGeAlD
Rufinamide—SCN1A—head—muscle cancer	0.00366	0.0217	CbGeAlD
Rufinamide—SCN2A—vagina—muscle cancer	0.00363	0.0215	CbGeAlD
Rufinamide—SCN3A—tendon—muscle cancer	0.00344	0.0204	CbGeAlD
Rufinamide—CES1—head—muscle cancer	0.00339	0.0201	CbGeAlD
Rufinamide—Urine output increased—Vincristine—muscle cancer	0.00338	0.0157	CcSEcCtD
Rufinamide—SCN2A—head—muscle cancer	0.00336	0.0199	CbGeAlD
Rufinamide—SCN3A—bone marrow—muscle cancer	0.00333	0.0198	CbGeAlD
Rufinamide—CES1—testis—muscle cancer	0.00327	0.0194	CbGeAlD
Rufinamide—SCN10A—head—muscle cancer	0.00324	0.0192	CbGeAlD
Rufinamide—SCN3A—vagina—muscle cancer	0.00319	0.0189	CbGeAlD
Rufinamide—SCN5A—vagina—muscle cancer	0.00319	0.0189	CbGeAlD
Rufinamide—Polyuria—Vincristine—muscle cancer	0.00309	0.0144	CcSEcCtD
Rufinamide—SCN3A—head—muscle cancer	0.00295	0.0175	CbGeAlD
Rufinamide—SCN5A—head—muscle cancer	0.00294	0.0174	CbGeAlD
Rufinamide—SCN3A—testis—muscle cancer	0.00285	0.0169	CbGeAlD
Rufinamide—SCN7A—Developmental Biology—MYF6—muscle cancer	0.00258	0.0283	CbGpPWpGaD
Rufinamide—SCN7A—Developmental Biology—MYF5—muscle cancer	0.00258	0.0283	CbGpPWpGaD
Rufinamide—Ataxia—Vincristine—muscle cancer	0.00255	0.0119	CcSEcCtD
Rufinamide—Neutropenia—Dactinomycin—muscle cancer	0.00245	0.0114	CcSEcCtD
Rufinamide—Pneumonia—Dactinomycin—muscle cancer	0.00235	0.011	CcSEcCtD
Rufinamide—SCN11A—Developmental Biology—MYF6—muscle cancer	0.0023	0.0252	CbGpPWpGaD
Rufinamide—SCN11A—Developmental Biology—MYF5—muscle cancer	0.0023	0.0252	CbGpPWpGaD
Rufinamide—ALB—testis—muscle cancer	0.00228	0.0135	CbGeAlD
Rufinamide—Nystagmus—Doxorubicin—muscle cancer	0.0022	0.0102	CcSEcCtD
Rufinamide—Neutropenia—Vincristine—muscle cancer	0.00219	0.0102	CcSEcCtD
Rufinamide—Dysuria—Vincristine—muscle cancer	0.00219	0.0102	CcSEcCtD
Rufinamide—Weight decreased—Vincristine—muscle cancer	0.00212	0.00988	CcSEcCtD
Rufinamide—Pneumonia—Vincristine—muscle cancer	0.0021	0.0098	CcSEcCtD
Rufinamide—SCN8A—Developmental Biology—MYF5—muscle cancer	0.0021	0.0231	CbGpPWpGaD
Rufinamide—SCN8A—Developmental Biology—MYF6—muscle cancer	0.0021	0.0231	CbGpPWpGaD
Rufinamide—CYP2E1—renal system—muscle cancer	0.00208	0.0123	CbGeAlD
Rufinamide—Bone disorder—Methotrexate—muscle cancer	0.00201	0.00935	CcSEcCtD
Rufinamide—Urinary tract disorder—Vincristine—muscle cancer	0.00185	0.00863	CcSEcCtD
Rufinamide—Urethral disorder—Vincristine—muscle cancer	0.00184	0.00857	CcSEcCtD
Rufinamide—Neutropenia—Etoposide—muscle cancer	0.00178	0.00827	CcSEcCtD
Rufinamide—Cardiac disorder—Vincristine—muscle cancer	0.00174	0.00811	CcSEcCtD
Rufinamide—Bone disorder—Doxorubicin—muscle cancer	0.00174	0.0081	CcSEcCtD
Rufinamide—Pneumonia—Etoposide—muscle cancer	0.0017	0.00794	CcSEcCtD
Rufinamide—SCN9A—Developmental Biology—MYF6—muscle cancer	0.0017	0.0186	CbGpPWpGaD
Rufinamide—SCN9A—Developmental Biology—MYF5—muscle cancer	0.0017	0.0186	CbGpPWpGaD
Rufinamide—Infestation NOS—Etoposide—muscle cancer	0.00169	0.00789	CcSEcCtD
Rufinamide—Infestation—Etoposide—muscle cancer	0.00169	0.00789	CcSEcCtD
Rufinamide—Nocturia—Doxorubicin—muscle cancer	0.00169	0.00789	CcSEcCtD
Rufinamide—Mediastinal disorder—Vincristine—muscle cancer	0.00169	0.00788	CcSEcCtD
Rufinamide—Anaemia—Dactinomycin—muscle cancer	0.00169	0.00787	CcSEcCtD
Rufinamide—CYP3A4—renal system—muscle cancer	0.00168	0.00993	CbGeAlD
Rufinamide—SCN7A—Developmental Biology—MYOG—muscle cancer	0.00166	0.0182	CbGpPWpGaD
Rufinamide—Mental disorder—Vincristine—muscle cancer	0.00164	0.00766	CcSEcCtD
Rufinamide—Urine output increased—Methotrexate—muscle cancer	0.00164	0.00764	CcSEcCtD
Rufinamide—Leukopenia—Dactinomycin—muscle cancer	0.00164	0.00763	CcSEcCtD
Rufinamide—CYP2E1—tendon—muscle cancer	0.00163	0.00963	CbGeAlD
Rufinamide—SCN3A—Developmental Biology—MYF6—muscle cancer	0.00162	0.0178	CbGpPWpGaD
Rufinamide—SCN3A—Developmental Biology—MYF5—muscle cancer	0.00162	0.0178	CbGpPWpGaD
Rufinamide—Gait disturbance—Doxorubicin—muscle cancer	0.00161	0.0075	CcSEcCtD
Rufinamide—Hepatobiliary disease—Etoposide—muscle cancer	0.0016	0.00746	CcSEcCtD
Rufinamide—Coordination abnormal—Doxorubicin—muscle cancer	0.0016	0.00745	CcSEcCtD
Rufinamide—Back pain—Vincristine—muscle cancer	0.00158	0.00736	CcSEcCtD
Rufinamide—SCN2A—Developmental Biology—MYF5—muscle cancer	0.00156	0.0171	CbGpPWpGaD
Rufinamide—SCN4A—Developmental Biology—MYF5—muscle cancer	0.00156	0.0171	CbGpPWpGaD
Rufinamide—SCN4A—Developmental Biology—MYF6—muscle cancer	0.00156	0.0171	CbGpPWpGaD
Rufinamide—SCN2A—Developmental Biology—MYF6—muscle cancer	0.00156	0.0171	CbGpPWpGaD
Rufinamide—Lymphadenopathy—Methotrexate—muscle cancer	0.00154	0.00719	CcSEcCtD
Rufinamide—Anaemia—Vincristine—muscle cancer	0.00151	0.00704	CcSEcCtD
Rufinamide—SCN10A—Developmental Biology—MYF6—muscle cancer	0.00151	0.0165	CbGpPWpGaD
Rufinamide—SCN1A—Developmental Biology—MYF6—muscle cancer	0.00151	0.0165	CbGpPWpGaD
Rufinamide—SCN10A—Developmental Biology—MYF5—muscle cancer	0.00151	0.0165	CbGpPWpGaD
Rufinamide—SCN1A—Developmental Biology—MYF5—muscle cancer	0.00151	0.0165	CbGpPWpGaD
Rufinamide—Urinary tract disorder—Etoposide—muscle cancer	0.0015	0.00699	CcSEcCtD
Rufinamide—Agitation—Vincristine—muscle cancer	0.0015	0.00699	CcSEcCtD
Rufinamide—Polyuria—Methotrexate—muscle cancer	0.0015	0.00698	CcSEcCtD
Rufinamide—Urethral disorder—Etoposide—muscle cancer	0.00149	0.00694	CcSEcCtD
Rufinamide—Infection—Dactinomycin—muscle cancer	0.00148	0.00691	CcSEcCtD
Rufinamide—SCN11A—Developmental Biology—MYOG—muscle cancer	0.00148	0.0162	CbGpPWpGaD
Rufinamide—Vertigo—Vincristine—muscle cancer	0.00147	0.00684	CcSEcCtD
Rufinamide—Leukopenia—Vincristine—muscle cancer	0.00146	0.00681	CcSEcCtD
Rufinamide—Thrombocytopenia—Dactinomycin—muscle cancer	0.00146	0.00681	CcSEcCtD
Rufinamide—Anorexia—Dactinomycin—muscle cancer	0.00142	0.00663	CcSEcCtD
Rufinamide—Eye disorder—Etoposide—muscle cancer	0.00142	0.00662	CcSEcCtD
Rufinamide—Convulsion—Vincristine—muscle cancer	0.00142	0.00659	CcSEcCtD
Rufinamide—Cardiac disorder—Etoposide—muscle cancer	0.00141	0.00657	CcSEcCtD
Rufinamide—CYP2E1—head—muscle cancer	0.00139	0.00825	CbGeAlD
Rufinamide—Immune system disorder—Etoposide—muscle cancer	0.00137	0.0064	CcSEcCtD
Rufinamide—SCN5A—Cardiac Progenitor Differentiation—IGF2—muscle cancer	0.00137	0.015	CbGpPWpGaD
Rufinamide—Mediastinal disorder—Etoposide—muscle cancer	0.00137	0.00638	CcSEcCtD
Rufinamide—SCN8A—Developmental Biology—MYOG—muscle cancer	0.00135	0.0149	CbGpPWpGaD
Rufinamide—CYP2E1—testis—muscle cancer	0.00135	0.00797	CbGeAlD
Rufinamide—Lymphadenopathy—Doxorubicin—muscle cancer	0.00134	0.00622	CcSEcCtD
Rufinamide—Infection—Vincristine—muscle cancer	0.00133	0.00617	CcSEcCtD
Rufinamide—Nervous system disorder—Vincristine—muscle cancer	0.00131	0.00609	CcSEcCtD
Rufinamide—Thrombocytopenia—Vincristine—muscle cancer	0.00131	0.00608	CcSEcCtD
Rufinamide—SCN5A—SIDS Susceptibility Pathways—TP73—muscle cancer	0.0013	0.0143	CbGpPWpGaD
Rufinamide—Decreased appetite—Dactinomycin—muscle cancer	0.0013	0.00604	CcSEcCtD
Rufinamide—Fatigue—Dactinomycin—muscle cancer	0.00129	0.00599	CcSEcCtD
Rufinamide—Back pain—Etoposide—muscle cancer	0.00128	0.00596	CcSEcCtD
Rufinamide—Anorexia—Vincristine—muscle cancer	0.00127	0.00592	CcSEcCtD
Rufinamide—Ataxia—Methotrexate—muscle cancer	0.00124	0.00577	CcSEcCtD
Rufinamide—Anaemia—Etoposide—muscle cancer	0.00122	0.0057	CcSEcCtD
Rufinamide—Increased appetite—Doxorubicin—muscle cancer	0.00121	0.00565	CcSEcCtD
Rufinamide—Insomnia—Vincristine—muscle cancer	0.00121	0.00562	CcSEcCtD
Rufinamide—Breast disorder—Methotrexate—muscle cancer	0.00119	0.00554	CcSEcCtD
Rufinamide—Vertigo—Etoposide—muscle cancer	0.00119	0.00554	CcSEcCtD
Rufinamide—Leukopenia—Etoposide—muscle cancer	0.00119	0.00552	CcSEcCtD
Rufinamide—Decreased appetite—Vincristine—muscle cancer	0.00116	0.0054	CcSEcCtD
Rufinamide—Gastrointestinal disorder—Vincristine—muscle cancer	0.00115	0.00536	CcSEcCtD
Rufinamide—Fatigue—Vincristine—muscle cancer	0.00115	0.00536	CcSEcCtD
Rufinamide—Convulsion—Etoposide—muscle cancer	0.00115	0.00534	CcSEcCtD
Rufinamide—Constipation—Vincristine—muscle cancer	0.00114	0.00531	CcSEcCtD
Rufinamide—Diplopia—Doxorubicin—muscle cancer	0.00114	0.00531	CcSEcCtD
Rufinamide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00112	0.00521	CcSEcCtD
Rufinamide—Hypersensitivity—Dactinomycin—muscle cancer	0.0011	0.00512	CcSEcCtD
Rufinamide—SCN9A—Developmental Biology—MYOG—muscle cancer	0.00109	0.012	CbGpPWpGaD
Rufinamide—Infection—Etoposide—muscle cancer	0.00107	0.005	CcSEcCtD
Rufinamide—Ataxia—Doxorubicin—muscle cancer	0.00107	0.00499	CcSEcCtD
Rufinamide—Asthenia—Dactinomycin—muscle cancer	0.00107	0.00499	CcSEcCtD
Rufinamide—Dysuria—Methotrexate—muscle cancer	0.00106	0.00496	CcSEcCtD
Rufinamide—Neutropenia—Methotrexate—muscle cancer	0.00106	0.00496	CcSEcCtD
Rufinamide—SCN5A—Developmental Biology—MYF6—muscle cancer	0.00106	0.0116	CbGpPWpGaD
Rufinamide—SCN5A—Developmental Biology—MYF5—muscle cancer	0.00106	0.0116	CbGpPWpGaD
Rufinamide—Thrombocytopenia—Etoposide—muscle cancer	0.00106	0.00493	CcSEcCtD
Rufinamide—Skin disorder—Etoposide—muscle cancer	0.00105	0.00489	CcSEcCtD
Rufinamide—SCN3A—Developmental Biology—MYOG—muscle cancer	0.00105	0.0115	CbGpPWpGaD
Rufinamide—Abdominal pain upper—Doxorubicin—muscle cancer	0.00104	0.00485	CcSEcCtD
Rufinamide—Breast disorder—Doxorubicin—muscle cancer	0.00103	0.0048	CcSEcCtD
Rufinamide—Anorexia—Etoposide—muscle cancer	0.00103	0.0048	CcSEcCtD
Rufinamide—SCN7A—Developmental Biology—MYOD1—muscle cancer	0.00103	0.0113	CbGpPWpGaD
Rufinamide—Diarrhoea—Dactinomycin—muscle cancer	0.00102	0.00476	CcSEcCtD
Rufinamide—Pneumonia—Methotrexate—muscle cancer	0.00102	0.00475	CcSEcCtD
Rufinamide—Nasopharyngitis—Doxorubicin—muscle cancer	0.00102	0.00475	CcSEcCtD
Rufinamide—Infestation NOS—Methotrexate—muscle cancer	0.00101	0.00473	CcSEcCtD
Rufinamide—Infestation—Methotrexate—muscle cancer	0.00101	0.00473	CcSEcCtD
Rufinamide—SCN4A—Developmental Biology—MYOG—muscle cancer	0.00101	0.011	CbGpPWpGaD
Rufinamide—SCN2A—Developmental Biology—MYOG—muscle cancer	0.00101	0.011	CbGpPWpGaD
Rufinamide—GRM5—GPCR ligand binding—PTCH1—muscle cancer	0.000998	0.011	CbGpPWpGaD
Rufinamide—Influenza—Doxorubicin—muscle cancer	0.000985	0.00459	CcSEcCtD
Rufinamide—Hypersensitivity—Vincristine—muscle cancer	0.000983	0.00458	CcSEcCtD
Rufinamide—CES1—Fluoropyrimidine Activity—TP53—muscle cancer	0.000979	0.0108	CbGpPWpGaD
Rufinamide—SCN10A—Developmental Biology—MYOG—muscle cancer	0.00097	0.0106	CbGpPWpGaD
Rufinamide—SCN1A—Developmental Biology—MYOG—muscle cancer	0.00097	0.0106	CbGpPWpGaD
Rufinamide—Haematuria—Methotrexate—muscle cancer	0.000968	0.00451	CcSEcCtD
Rufinamide—SCN5A—Cardiac Progenitor Differentiation—KIT—muscle cancer	0.000961	0.0106	CbGpPWpGaD
Rufinamide—Somnolence—Etoposide—muscle cancer	0.000961	0.00447	CcSEcCtD
Rufinamide—Hepatobiliary disease—Methotrexate—muscle cancer	0.00096	0.00447	CcSEcCtD
Rufinamide—Epistaxis—Methotrexate—muscle cancer	0.000957	0.00446	CcSEcCtD
Rufinamide—Asthenia—Vincristine—muscle cancer	0.000957	0.00446	CcSEcCtD
Rufinamide—Vomiting—Dactinomycin—muscle cancer	0.000949	0.00442	CcSEcCtD
Rufinamide—Bronchitis—Doxorubicin—muscle cancer	0.000948	0.00441	CcSEcCtD
Rufinamide—Rash—Dactinomycin—muscle cancer	0.000941	0.00438	CcSEcCtD
Rufinamide—Decreased appetite—Etoposide—muscle cancer	0.000939	0.00437	CcSEcCtD
Rufinamide—SCN7A—Developmental Biology—MED12—muscle cancer	0.000938	0.0103	CbGpPWpGaD
Rufinamide—Gastrointestinal disorder—Etoposide—muscle cancer	0.000933	0.00434	CcSEcCtD
Rufinamide—CES1—E2F transcription factor network—CDKN2A—muscle cancer	0.000932	0.0102	CbGpPWpGaD
Rufinamide—Fatigue—Etoposide—muscle cancer	0.000932	0.00434	CcSEcCtD
Rufinamide—Constipation—Etoposide—muscle cancer	0.000924	0.0043	CcSEcCtD
Rufinamide—Dysuria—Doxorubicin—muscle cancer	0.000922	0.00429	CcSEcCtD
Rufinamide—Neutropenia—Doxorubicin—muscle cancer	0.000922	0.00429	CcSEcCtD
Rufinamide—SCN11A—Developmental Biology—MYOD1—muscle cancer	0.000914	0.01	CbGpPWpGaD
Rufinamide—Diarrhoea—Vincristine—muscle cancer	0.000913	0.00425	CcSEcCtD
Rufinamide—Pollakiuria—Doxorubicin—muscle cancer	0.00091	0.00424	CcSEcCtD
Rufinamide—Urinary tract disorder—Methotrexate—muscle cancer	0.0009	0.00419	CcSEcCtD
Rufinamide—Urethral disorder—Methotrexate—muscle cancer	0.000893	0.00416	CcSEcCtD
Rufinamide—Weight decreased—Doxorubicin—muscle cancer	0.000892	0.00415	CcSEcCtD
Rufinamide—Nausea—Dactinomycin—muscle cancer	0.000887	0.00413	CcSEcCtD
Rufinamide—Pneumonia—Doxorubicin—muscle cancer	0.000884	0.00412	CcSEcCtD
Rufinamide—Dizziness—Vincristine—muscle cancer	0.000882	0.00411	CcSEcCtD
Rufinamide—Infestation NOS—Doxorubicin—muscle cancer	0.000879	0.00409	CcSEcCtD
Rufinamide—Infestation—Doxorubicin—muscle cancer	0.000879	0.00409	CcSEcCtD
Rufinamide—Eye disorder—Methotrexate—muscle cancer	0.000851	0.00396	CcSEcCtD
Rufinamide—Vomiting—Vincristine—muscle cancer	0.000848	0.00395	CcSEcCtD
Rufinamide—Cardiac disorder—Methotrexate—muscle cancer	0.000845	0.00394	CcSEcCtD
Rufinamide—GRM5—GPCR ligand binding—CNR1—muscle cancer	0.000842	0.00925	CbGpPWpGaD
Rufinamide—Rash—Vincristine—muscle cancer	0.000841	0.00392	CcSEcCtD
Rufinamide—Dermatitis—Vincristine—muscle cancer	0.00084	0.00391	CcSEcCtD
Rufinamide—Haematuria—Doxorubicin—muscle cancer	0.000838	0.0039	CcSEcCtD
Rufinamide—SCN11A—Developmental Biology—MED12—muscle cancer	0.000836	0.00918	CbGpPWpGaD
Rufinamide—SCN8A—Developmental Biology—MYOD1—muscle cancer	0.000836	0.00918	CbGpPWpGaD
Rufinamide—Headache—Vincristine—muscle cancer	0.000836	0.00389	CcSEcCtD
Rufinamide—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000831	0.00387	CcSEcCtD
Rufinamide—Epistaxis—Doxorubicin—muscle cancer	0.000829	0.00386	CcSEcCtD
Rufinamide—Sinusitis—Doxorubicin—muscle cancer	0.000824	0.00384	CcSEcCtD
Rufinamide—Immune system disorder—Methotrexate—muscle cancer	0.000823	0.00383	CcSEcCtD
Rufinamide—Mediastinal disorder—Methotrexate—muscle cancer	0.000821	0.00382	CcSEcCtD
Rufinamide—Mental disorder—Methotrexate—muscle cancer	0.000798	0.00372	CcSEcCtD
Rufinamide—Hypersensitivity—Etoposide—muscle cancer	0.000796	0.00371	CcSEcCtD
Rufinamide—Malnutrition—Methotrexate—muscle cancer	0.000793	0.00369	CcSEcCtD
Rufinamide—Nausea—Vincristine—muscle cancer	0.000792	0.00369	CcSEcCtD
Rufinamide—Rhinitis—Doxorubicin—muscle cancer	0.000791	0.00368	CcSEcCtD
Rufinamide—Urinary tract disorder—Doxorubicin—muscle cancer	0.000779	0.00363	CcSEcCtD
Rufinamide—Asthenia—Etoposide—muscle cancer	0.000775	0.00361	CcSEcCtD
Rufinamide—Urethral disorder—Doxorubicin—muscle cancer	0.000773	0.0036	CcSEcCtD
Rufinamide—GRM5—Signaling Pathways—KIDINS220—muscle cancer	0.000769	0.00844	CbGpPWpGaD
Rufinamide—Back pain—Methotrexate—muscle cancer	0.000767	0.00357	CcSEcCtD
Rufinamide—SCN8A—Developmental Biology—MED12—muscle cancer	0.000765	0.00839	CbGpPWpGaD
Rufinamide—Pruritus—Etoposide—muscle cancer	0.000764	0.00356	CcSEcCtD
Rufinamide—Vision blurred—Methotrexate—muscle cancer	0.000747	0.00348	CcSEcCtD
Rufinamide—Diarrhoea—Etoposide—muscle cancer	0.000739	0.00344	CcSEcCtD
Rufinamide—Eye disorder—Doxorubicin—muscle cancer	0.000737	0.00343	CcSEcCtD
Rufinamide—Anaemia—Methotrexate—muscle cancer	0.000733	0.00341	CcSEcCtD
Rufinamide—Cardiac disorder—Doxorubicin—muscle cancer	0.000732	0.00341	CcSEcCtD
Rufinamide—Dizziness—Etoposide—muscle cancer	0.000715	0.00333	CcSEcCtD
Rufinamide—Immune system disorder—Doxorubicin—muscle cancer	0.000712	0.00332	CcSEcCtD
Rufinamide—Vertigo—Methotrexate—muscle cancer	0.000712	0.00332	CcSEcCtD
Rufinamide—Mediastinal disorder—Doxorubicin—muscle cancer	0.000711	0.00331	CcSEcCtD
Rufinamide—Leukopenia—Methotrexate—muscle cancer	0.00071	0.00331	CcSEcCtD
Rufinamide—Mental disorder—Doxorubicin—muscle cancer	0.000691	0.00322	CcSEcCtD
Rufinamide—Convulsion—Methotrexate—muscle cancer	0.000687	0.0032	CcSEcCtD
Rufinamide—Vomiting—Etoposide—muscle cancer	0.000687	0.0032	CcSEcCtD
Rufinamide—Malnutrition—Doxorubicin—muscle cancer	0.000687	0.0032	CcSEcCtD
Rufinamide—SCN5A—Developmental Biology—MYOG—muscle cancer	0.000682	0.00749	CbGpPWpGaD
Rufinamide—Rash—Etoposide—muscle cancer	0.000681	0.00317	CcSEcCtD
Rufinamide—Dermatitis—Etoposide—muscle cancer	0.000681	0.00317	CcSEcCtD
Rufinamide—Headache—Etoposide—muscle cancer	0.000677	0.00315	CcSEcCtD
Rufinamide—SCN9A—Developmental Biology—MYOD1—muscle cancer	0.000676	0.00742	CbGpPWpGaD
Rufinamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.00067	0.00312	CcSEcCtD
Rufinamide—Back pain—Doxorubicin—muscle cancer	0.000664	0.00309	CcSEcCtD
Rufinamide—Vision blurred—Doxorubicin—muscle cancer	0.000647	0.00301	CcSEcCtD
Rufinamide—SCN3A—Developmental Biology—MYOD1—muscle cancer	0.000647	0.0071	CbGpPWpGaD
Rufinamide—Infection—Methotrexate—muscle cancer	0.000643	0.00299	CcSEcCtD
Rufinamide—Nausea—Etoposide—muscle cancer	0.000642	0.00299	CcSEcCtD
Rufinamide—Nervous system disorder—Methotrexate—muscle cancer	0.000635	0.00296	CcSEcCtD
Rufinamide—Anaemia—Doxorubicin—muscle cancer	0.000635	0.00296	CcSEcCtD
Rufinamide—Thrombocytopenia—Methotrexate—muscle cancer	0.000634	0.00295	CcSEcCtD
Rufinamide—Agitation—Doxorubicin—muscle cancer	0.000631	0.00294	CcSEcCtD
Rufinamide—Skin disorder—Methotrexate—muscle cancer	0.000629	0.00293	CcSEcCtD
Rufinamide—SCN2A—Developmental Biology—MYOD1—muscle cancer	0.000621	0.00682	CbGpPWpGaD
Rufinamide—SCN4A—Developmental Biology—MYOD1—muscle cancer	0.000621	0.00682	CbGpPWpGaD
Rufinamide—SCN9A—Developmental Biology—MED12—muscle cancer	0.000619	0.00679	CbGpPWpGaD
Rufinamide—Vertigo—Doxorubicin—muscle cancer	0.000617	0.00287	CcSEcCtD
Rufinamide—Anorexia—Methotrexate—muscle cancer	0.000617	0.00287	CcSEcCtD
Rufinamide—Leukopenia—Doxorubicin—muscle cancer	0.000615	0.00286	CcSEcCtD
Rufinamide—SCN1A—Developmental Biology—MYOD1—muscle cancer	0.000599	0.00658	CbGpPWpGaD
Rufinamide—SCN10A—Developmental Biology—MYOD1—muscle cancer	0.000599	0.00658	CbGpPWpGaD
Rufinamide—Convulsion—Doxorubicin—muscle cancer	0.000595	0.00277	CcSEcCtD
Rufinamide—SCN3A—Developmental Biology—MED12—muscle cancer	0.000592	0.00649	CbGpPWpGaD
Rufinamide—Insomnia—Methotrexate—muscle cancer	0.000585	0.00273	CcSEcCtD
Rufinamide—Anxiety—Doxorubicin—muscle cancer	0.000583	0.00271	CcSEcCtD
Rufinamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000581	0.0027	CcSEcCtD
Rufinamide—Somnolence—Methotrexate—muscle cancer	0.000575	0.00268	CcSEcCtD
Rufinamide—Dyspepsia—Methotrexate—muscle cancer	0.00057	0.00265	CcSEcCtD
Rufinamide—SCN2A—Developmental Biology—MED12—muscle cancer	0.000568	0.00624	CbGpPWpGaD
Rufinamide—SCN4A—Developmental Biology—MED12—muscle cancer	0.000568	0.00624	CbGpPWpGaD
Rufinamide—Decreased appetite—Methotrexate—muscle cancer	0.000563	0.00262	CcSEcCtD
Rufinamide—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000559	0.0026	CcSEcCtD
Rufinamide—Fatigue—Methotrexate—muscle cancer	0.000558	0.0026	CcSEcCtD
Rufinamide—Infection—Doxorubicin—muscle cancer	0.000557	0.00259	CcSEcCtD
Rufinamide—Nervous system disorder—Doxorubicin—muscle cancer	0.00055	0.00256	CcSEcCtD
Rufinamide—Thrombocytopenia—Doxorubicin—muscle cancer	0.000549	0.00256	CcSEcCtD
Rufinamide—SCN10A—Developmental Biology—MED12—muscle cancer	0.000548	0.00602	CbGpPWpGaD
Rufinamide—SCN1A—Developmental Biology—MED12—muscle cancer	0.000548	0.00602	CbGpPWpGaD
Rufinamide—Skin disorder—Doxorubicin—muscle cancer	0.000544	0.00254	CcSEcCtD
Rufinamide—Anorexia—Doxorubicin—muscle cancer	0.000534	0.00249	CcSEcCtD
Rufinamide—SCN7A—Developmental Biology—FOXO1—muscle cancer	0.000515	0.00565	CbGpPWpGaD
Rufinamide—GRM5—Signaling by GPCR—PTCH1—muscle cancer	0.000512	0.00562	CbGpPWpGaD
Rufinamide—Insomnia—Doxorubicin—muscle cancer	0.000507	0.00236	CcSEcCtD
Rufinamide—Somnolence—Doxorubicin—muscle cancer	0.000498	0.00232	CcSEcCtD
Rufinamide—Dyspepsia—Doxorubicin—muscle cancer	0.000493	0.0023	CcSEcCtD
Rufinamide—Decreased appetite—Doxorubicin—muscle cancer	0.000487	0.00227	CcSEcCtD
Rufinamide—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000484	0.00225	CcSEcCtD
Rufinamide—Fatigue—Doxorubicin—muscle cancer	0.000483	0.00225	CcSEcCtD
Rufinamide—Constipation—Doxorubicin—muscle cancer	0.000479	0.00223	CcSEcCtD
Rufinamide—Hypersensitivity—Methotrexate—muscle cancer	0.000477	0.00222	CcSEcCtD
Rufinamide—GRM5—GPCR downstream signaling—CNR1—muscle cancer	0.000476	0.00523	CbGpPWpGaD
Rufinamide—Asthenia—Methotrexate—muscle cancer	0.000464	0.00216	CcSEcCtD
Rufinamide—SCN11A—Developmental Biology—FOXO1—muscle cancer	0.000459	0.00504	CbGpPWpGaD
Rufinamide—Pruritus—Methotrexate—muscle cancer	0.000458	0.00213	CcSEcCtD
Rufinamide—Diarrhoea—Methotrexate—muscle cancer	0.000443	0.00206	CcSEcCtD
Rufinamide—GRM5—Signaling by GPCR—CNR1—muscle cancer	0.000432	0.00475	CbGpPWpGaD
Rufinamide—Dizziness—Methotrexate—muscle cancer	0.000428	0.00199	CcSEcCtD
Rufinamide—SCN5A—Developmental Biology—MYOD1—muscle cancer	0.000421	0.00462	CbGpPWpGaD
Rufinamide—SCN8A—Developmental Biology—FOXO1—muscle cancer	0.00042	0.00461	CbGpPWpGaD
Rufinamide—Hypersensitivity—Doxorubicin—muscle cancer	0.000413	0.00192	CcSEcCtD
Rufinamide—Vomiting—Methotrexate—muscle cancer	0.000412	0.00192	CcSEcCtD
Rufinamide—Rash—Methotrexate—muscle cancer	0.000408	0.0019	CcSEcCtD
Rufinamide—Dermatitis—Methotrexate—muscle cancer	0.000408	0.0019	CcSEcCtD
Rufinamide—Headache—Methotrexate—muscle cancer	0.000405	0.00189	CcSEcCtD
Rufinamide—Asthenia—Doxorubicin—muscle cancer	0.000402	0.00187	CcSEcCtD
Rufinamide—Pruritus—Doxorubicin—muscle cancer	0.000396	0.00185	CcSEcCtD
Rufinamide—SCN5A—Developmental Biology—MED12—muscle cancer	0.000385	0.00423	CbGpPWpGaD
Rufinamide—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000385	0.00422	CbGpPWpGaD
Rufinamide—Nausea—Methotrexate—muscle cancer	0.000384	0.00179	CcSEcCtD
Rufinamide—Diarrhoea—Doxorubicin—muscle cancer	0.000383	0.00179	CcSEcCtD
Rufinamide—CYP2E1—Tryptophan metabolism—MDM2—muscle cancer	0.000372	0.00408	CbGpPWpGaD
Rufinamide—ALB—Platelet degranulation—IGF2—muscle cancer	0.000372	0.00408	CbGpPWpGaD
Rufinamide—Dizziness—Doxorubicin—muscle cancer	0.000371	0.00173	CcSEcCtD
Rufinamide—Vomiting—Doxorubicin—muscle cancer	0.000356	0.00166	CcSEcCtD
Rufinamide—ALB—Response to elevated platelet cytosolic Ca2+—IGF2—muscle cancer	0.000354	0.00389	CbGpPWpGaD
Rufinamide—Rash—Doxorubicin—muscle cancer	0.000353	0.00165	CcSEcCtD
Rufinamide—Dermatitis—Doxorubicin—muscle cancer	0.000353	0.00164	CcSEcCtD
Rufinamide—Headache—Doxorubicin—muscle cancer	0.000351	0.00164	CcSEcCtD
Rufinamide—SCN9A—Developmental Biology—FOXO1—muscle cancer	0.00034	0.00373	CbGpPWpGaD
Rufinamide—Nausea—Doxorubicin—muscle cancer	0.000333	0.00155	CcSEcCtD
Rufinamide—SCN7A—Axon guidance—VEGFA—muscle cancer	0.000329	0.00361	CbGpPWpGaD
Rufinamide—SCN3A—Developmental Biology—FOXO1—muscle cancer	0.000325	0.00356	CbGpPWpGaD
Rufinamide—SCN2A—Developmental Biology—FOXO1—muscle cancer	0.000312	0.00342	CbGpPWpGaD
Rufinamide—SCN4A—Developmental Biology—FOXO1—muscle cancer	0.000312	0.00342	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—PTCH1—muscle cancer	0.000303	0.00332	CbGpPWpGaD
Rufinamide—SCN10A—Developmental Biology—FOXO1—muscle cancer	0.000301	0.0033	CbGpPWpGaD
Rufinamide—SCN1A—Developmental Biology—FOXO1—muscle cancer	0.000301	0.0033	CbGpPWpGaD
Rufinamide—SCN11A—Axon guidance—VEGFA—muscle cancer	0.000293	0.00322	CbGpPWpGaD
Rufinamide—SCN8A—Axon guidance—VEGFA—muscle cancer	0.000268	0.00294	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—FOXO4—muscle cancer	0.00026	0.00286	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—CNR1—muscle cancer	0.000255	0.0028	CbGpPWpGaD
Rufinamide—SCN5A—SIDS Susceptibility Pathways—VEGFA—muscle cancer	0.000242	0.00266	CbGpPWpGaD
Rufinamide—SCN7A—Developmental Biology—VEGFA—muscle cancer	0.000235	0.00258	CbGpPWpGaD
Rufinamide—SCN9A—Axon guidance—VEGFA—muscle cancer	0.000217	0.00238	CbGpPWpGaD
Rufinamide—SCN5A—Developmental Biology—FOXO1—muscle cancer	0.000212	0.00232	CbGpPWpGaD
Rufinamide—SCN11A—Developmental Biology—VEGFA—muscle cancer	0.000209	0.0023	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—IGF2—muscle cancer	0.000209	0.00229	CbGpPWpGaD
Rufinamide—SCN3A—Axon guidance—VEGFA—muscle cancer	0.000207	0.00228	CbGpPWpGaD
Rufinamide—SCN2A—Axon guidance—VEGFA—muscle cancer	0.000199	0.00219	CbGpPWpGaD
Rufinamide—SCN4A—Axon guidance—VEGFA—muscle cancer	0.000199	0.00219	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—FOXO1—muscle cancer	0.000192	0.00211	CbGpPWpGaD
Rufinamide—SCN10A—Axon guidance—VEGFA—muscle cancer	0.000192	0.00211	CbGpPWpGaD
Rufinamide—SCN1A—Axon guidance—VEGFA—muscle cancer	0.000192	0.00211	CbGpPWpGaD
Rufinamide—SCN8A—Developmental Biology—VEGFA—muscle cancer	0.000191	0.0021	CbGpPWpGaD
Rufinamide—ALB—Selenium Micronutrient Network—PTGS2—muscle cancer	0.000183	0.00201	CbGpPWpGaD
Rufinamide—ALB—Hemostasis—ANGPT2—muscle cancer	0.000175	0.00192	CbGpPWpGaD
Rufinamide—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	0.000173	0.00189	CbGpPWpGaD
Rufinamide—ALB—Platelet activation, signaling and aggregation—IGF2—muscle cancer	0.000165	0.00181	CbGpPWpGaD
Rufinamide—ALB—Platelet degranulation—VEGFA—muscle cancer	0.000156	0.00171	CbGpPWpGaD
Rufinamide—SCN9A—Developmental Biology—VEGFA—muscle cancer	0.000155	0.0017	CbGpPWpGaD
Rufinamide—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—muscle cancer	0.000149	0.00163	CbGpPWpGaD
Rufinamide—SCN3A—Developmental Biology—VEGFA—muscle cancer	0.000148	0.00162	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—KIT—muscle cancer	0.000146	0.00161	CbGpPWpGaD
Rufinamide—SCN2A—Developmental Biology—VEGFA—muscle cancer	0.000142	0.00156	CbGpPWpGaD
Rufinamide—SCN4A—Developmental Biology—VEGFA—muscle cancer	0.000142	0.00156	CbGpPWpGaD
Rufinamide—ALB—Folate Metabolism—TP53—muscle cancer	0.000137	0.00151	CbGpPWpGaD
Rufinamide—SCN1A—Developmental Biology—VEGFA—muscle cancer	0.000137	0.0015	CbGpPWpGaD
Rufinamide—SCN10A—Developmental Biology—VEGFA—muscle cancer	0.000137	0.0015	CbGpPWpGaD
Rufinamide—SCN5A—Axon guidance—VEGFA—muscle cancer	0.000135	0.00148	CbGpPWpGaD
Rufinamide—ALB—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.00013	0.00142	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—FH—muscle cancer	0.000119	0.00131	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—MDM2—muscle cancer	0.000115	0.00127	CbGpPWpGaD
Rufinamide—ALB—Metabolism—FH—muscle cancer	0.000102	0.00112	CbGpPWpGaD
Rufinamide—SCN5A—Developmental Biology—VEGFA—muscle cancer	9.64e-05	0.00106	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—VEGFA—muscle cancer	8.76e-05	0.000961	CbGpPWpGaD
Rufinamide—ALB—Hemostasis—IGF2—muscle cancer	8.5e-05	0.000933	CbGpPWpGaD
Rufinamide—ALB—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	6.92e-05	0.000759	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—MED12—muscle cancer	6.73e-05	0.000738	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—TP53—muscle cancer	6.62e-05	0.000726	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—ENO2—muscle cancer	6.13e-05	0.000673	CbGpPWpGaD
Rufinamide—ALB—Metabolism—MED12—muscle cancer	5.78e-05	0.000634	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—FH—muscle cancer	5.52e-05	0.000606	CbGpPWpGaD
Rufinamide—ALB—Metabolism—ENO2—muscle cancer	5.27e-05	0.000578	CbGpPWpGaD
Rufinamide—ALB—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	4.12e-05	0.000452	CbGpPWpGaD
Rufinamide—ALB—Hemostasis—VEGFA—muscle cancer	3.57e-05	0.000391	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—MED12—muscle cancer	3.12e-05	0.000343	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—ENO2—muscle cancer	2.84e-05	0.000312	CbGpPWpGaD
Rufinamide—ALB—Hemostasis—TP53—muscle cancer	2.69e-05	0.000296	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—PTGS2—muscle cancer	2.14e-05	0.000234	CbGpPWpGaD
Rufinamide—ALB—Metabolism—PTGS2—muscle cancer	1.84e-05	0.000201	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—PTGS2—muscle cancer	9.91e-06	0.000109	CbGpPWpGaD
